Chemoprevention of Premalignant and Early Malignant Lesions of the Prostate

Guest Editors

David G. Bostwick
Laboratory Medicine and Pathology
Mayo Clinic
Rochester, MN

Peter T. Scardino
Scott Department of Urology
Baylor College of Medicine
Houston, TX

Gary J. Kelloff
Division of Cancer Prevention and Control
Chemoprevention Branch
National Cancer Institute
National Institutes of Health
Bethesda, MD

Charles W. Boone
Division of Cancer Prevention and Control
Chemoprevention Branch
National Cancer Institute
National Institutes of Health
Bethesda, MD
Preface...........................................................................................................................................vi

Introductory Remarks: Development of Chemopreventive Agents for Prostate Cancer
Gary J. Kelloff, Charles W. Boone, Winfred F. Malone, Vernon E. Steele, and Linda A. Doody .......... 1

PREMALIGNANT AND EARLY MALIGNANT LESIONS OF THE PROSTATE
Overview
David G. Bostwick ......................................................................................................................... 9

Prostatic Intraepithelial Neoplasia (PIN): Current Concepts
David G. Bostwick ......................................................................................................................... 10

The Natural History of Adenocarcinoma of the Prostate
Ian M. Thompson and Gerald W. Chodak ....................................................................................... 20

New Relationships Between Prostatic Intraepithelial Neoplasia and Prostatic Carcinoma
Ray B. Nagle, Michel Petein, Michael Brawer, G. Tim Bowden, and Anne E. Cress ....................... 26

MARKERS OF PREMALIGNANT AND EARLY MALIGNANT LESIONS
Overview
Michael K. Brawer .......................................................................................................................... 30

Prostate-Specific Antigen and Diagnosing Early Malignancies of the Prostate
Joseph E. Oesterling ....................................................................................................................... 31

DNA Ploidy: Early Malignant Lesions
Michael M. Lieber .......................................................................................................................... 44

Aneuploidy and Nuclear Features of Prostatic Intraepithelial Neoplasia (PIN)
Rodolfo Montironi, Marina Scarpelli, Cristina Magi Galluzzi, and Lucilla Diamanti ....................... 47

Transforming Growth Factor β1 as a Biomarker for Prostate Cancer
Timothy C. Thompson, Luan D. Truong, Terry L. Timme, Dov Kadmon, Bryan K. McCune,
Kathleen C. Flanders, Peter T. Scardino, and Sang Hee Park ....................................................... 54

(continued on next page)
Quantitative Morphometric Analysis of the Microcirculation in Prostate Carcinoma
Michael K. Brawer, Steven A. Bigler, and Robert E. Deering ........................................... 62

Invited Comment: Current and Proposed Biologic Markers in Prostate Cancer
David G. Bostwick, Rodolfo Montironi, Raymond Nagle, Thomas Pretlow, Gary Miller,
Thomas Wheeler, Jonathan Epstein, and Wael Sakr .................................................. 65

METHODS OF EARLY DETECTION
Overview
William J. Catalona ........................................................................................................... 68

The Role of Digital Rectal Examination, Transrectal Ultrasound, and Prostate Specific
Antigen for the Detection of Confined and Clinically Relevant Prostate Cancer
Fred Lee and Peter J. Littrup ............................................................................................... 69

Prostate Cancer Tumor Location as Predicted by Digital Rectal Examination Transferred to
Ultrasound and Ultrasound-Guided Prostate Needle Biopsy
Michael K. Brawer, Nelson R. Ploch, and Steven A. Bigler ........................................... 74

Cancer Detected Incidental to Simple Prostatectomy (Stage A1)
Jonathan I. Epstein ........................................................................................................... 78

MODELS FOR PREMALIGNANT AND EARLY MALIGNANT CANCER
Overview
Richard C. Moon .............................................................................................................. 83

The Lobund-Wistar Rat Model of Prostate Cancer
Morris Pollard .................................................................................................................. 84

Animal Models for the Study of Prostate Carcinogenesis
Maarten C. Bosland ........................................................................................................... 89

Human Prostate Cancer Model: Roles of Growth Factors and Extracellular Matrices
Leland W.K. Chung, Wei Li, Martin E. Gleave, Jer-Tsong Hsieh, Hsi-Chin Wu, Robert A. Sikes,
Haiyen E. Zhau, Mark G. Bandyk, Christopher J. Logothetis, Jeffrey S. Rubin,
and Andrew C. von Eschenbach ..................................................................................... 99

CHEMOPREVENTION STRATEGIES
Overview
Glenn J. Gormley ............................................................................................................. 106

Hormonal Balance and the Risk of Prostatic Cancer
John T. Isaacs .................................................................................................................. 107

Castration-Like Effects on the Human Prostate of a 5α-Reductase Inhibitor, Finasteride
Jack Geller and Lida Sionit .............................................................................................. 109

Chemoprevention Strategies for Prostate Cancer: The Role of 5α-Reductase Inhibitors
Glenn J. Gormley ............................................................................................................. 113

Neoadjuvant Hormonal Manipulation: A Strategy for Chemoprevention Trials
William R. Fair, Armen Aprikian, and Victor Reuter ....................................................... 118

(continued on next page)
Chemoprevention in Prostate Cancer: The Role of Difluoromethylornithine (DFMO)
Dov Kadmon ........................................................................................................... 122

The Inhibition of the Paracrine Progression of Prostate Cancer as an Approach to Early Therapy of Prostatic Carcinoma
Christopher Logothetis and Naseema Hoosein ...................................................... 128

Invited Comment: Possible Enhancement of Prostate Carcinogenesis by Some Chemopreventive Agents
Maarten C. Bosland .................................................................................................. 135

PANEL CONSENSUS STATEMENTS
When Is Intervention Warranted?

Chemoprevention of Prostate Cancer: Guidelines for Possible Intervention Strategies
E. David Crawford, William R. Fair, Gary J. Kellogg, Michael M. Lieber, Gary J. Miller, Peter T. Scardino, and Edward P. DeAntoni ......................................................... 140

Author Index .............................................................................................................. 146

Subject Index ............................................................................................................. 147


BACK COVER: Image of transrectal ultrasound showing nodule of adenocarcinoma (arrows) from the work of Dr. Fred Lee. Contributed by Dr. Charles W. Boone, Chemoprevention Branch (Bethesda, MD) in conjunction with the Medical Arts and Photography Branch, Graphics Section, National Institutes of Health.